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ABSTRACT
Purpose: Adoptive cell immunotherapy involves an ex vivo expansion of 
autologous cytokine-induced killer (CIK) cells before their reinfusion into the host. 
We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-
temozolomide (TMZ) for the treatment of newly diagnosed glioblastomas.
Experimental design: In this multi-center, open-label, phase 3 study, we 
randomly assigned patients with newly diagnosed glioblastoma to receive CIK cell 
immunotherapy combined with standard TMZ chemoradiotherapy (CIK immunotherapy 
group) or standard TMZ chemoradiotherapy alone (control group). The efficacy 
endpoints were analyzed in the intention-to-treat set and in the per protocol set.
Results: Between December 2008 and October 2012, a total of 180 patients were 
randomly assigned to the CIK immunotherapy (n = 91) or control group (n = 89). 
In the intention-to-treat analysis set, median PFS was 8.1 months (95% confidence 
interval (CI), 5.8 to 8.5 months) in the CIK immunotherapy group, as compared to 
5.4 months (95% CI, 3.3 to 7.9 months) in the control group (one-sided log-rank, p = 
0.0401). Overall survival did not differ significantly between two groups. Grade 3 or 
higher adverse events, health-related quality of life and performance status between 
two groups did not show a significant difference. 
Conclusions: The addition of CIK cells immunotherapy to standard 
chemoradiotherapy with TMZ improved PFS. However, the CIK immunotherapy group 
did not show evidence of a beneficial effect on overall survival.
INTRODUCTION
Glioblastoma (GBM) is the most aggressive 
primary parenchymal brain tumor, which has a median 
survival of only 14.6-16 months. [1, 2] The current 
standard therapy is safe maximal resection followed 
by concurrent radiotherapy and chemotherapy with 
temozolomide (TMZ) and subsequent TMZ treatment. 
Despite current treatment regimens, there has been only 
modest improvement in survival. The dismal prognosis 
necessitates exploration of new or adjuvant treatment 
options to improve survival.
 Over the past several centuries, whether the 
body’s innate immune system could work to recognize 
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and attack a malignant tumor has been a matter of 
debate. Immunotherapy was not considered an effective 
treatment option in brain tumors because of the blood 
brain barrier (BBB), as well as the absence of the 
lymphatic drainage system. [3] Cancer immunotherapy 
remains an available treatment option for certain cancer 
types. Adoptive cell immunotherapy relies on an ex vivo 
expansion of the autologous tumor-specific effector 
cells before their reinfusion into the host. [4] Adoptive 
cell therapy is a highly personalized cancer therapy that 
involves administration to the cancer-bearing host of 
immune cells with direct anticancer activity. Cytokine-
induced killer (CIK) cells are major histocompatibility 
(MHC)-unrestricted cytotoxic lymphocytes that can be 
generated in vitro from peripheral blood mononuclear 
cells and cultured with the addition of interferon (IFN)-γ, 
interleukin (IL)-2, and CD3 monoclonal antibody 
(CD3mAb). [5] They have a high proliferative rate and 
anti-tumor activity, and can serve as an alternative cellular 
immunotherapy. [6] Recently, the application of CIK 
cells has evolved from experimental studies to phase II 
clinical studies. [3, 4, 6-11] Since the first clinical trial 
of adoptive immunotherapy using CIK cells in 1999, 
a growing number of trials have suggested that CIK 
therapy is associated with a significantly prolonged 
mean survival time and disease control rate. [12] Recent 
studies demonstrated that immunotherapy with CIK cells 
improved clinical outcome and promoted the quality of 
life (QoL) in cancer patients. [4, 5, 11, 13, 14] Wu, et al. 
reported the result of phase II study that chemotherapy plus 
CIK cells had potential benefits compared to chemotherapy 
alone in patients with advanced non-small cell lung cancer 
and autologous CIK cell transfusion had no obvious side-
effects4. Recent literatures on CIK cells have demonstrated 
convincing evidence of the feasibility and very high safety 
profile in several clinical trials. [7, 10, 11, 15] Lee, et al. 
demonstrated adjuvant CIK immunotherapy improved 
survival for recurrent hepatocellular carcinoma in the 
phase III study15. Retrospective reviews regarding the 
adverse events by autologous CIK cells immunotherapy 
revealed that their adverse effects represented minor, self-
limiting, and not serious, as most of the adverse events 
were resolved without additional management within 24 
hours. [8, 9, 13, 15] However, there is no clinical evidence 
for adoptive immunotherapy using CIK cells to prolong 
the survival and promote the QoL in patients with GBM. 
 Here, we performed a multi-center, randomized, 
open-label phase III clinical trial to assess the efficacy 
and safety of autologous CIK cells administration for 
adoptive immunotherapy combined with the standard 
TMZ treatment in Korea with newly diagnosed GBMs. 
MATERIALS AND METHODS
Study design 
From December 2008 to October 2012, a 
prospective, randomized, phase III multi-center trial was 
conducted at 7 institutes in Korea. Patients were required 
to be registered before the start of concomitant chemo-
radiotherapy with TMZ. Before randomization and after 
informed consent, an independent pathology review was 
done. Patients who met eligibility criteria were randomly 
assigned, in a 1 : 1 ratio, to receive either autologous 
CIK cells immunotherapy combined with standard TMZ 
chemoradiotherapy (CIK immunotherapy group) or 
standard TMZ chemoradiotherapy alone (control group). 
Random assignment was performed through a central 
telephone system using computer-generated permuted-
block with a size of 4 or 6 and stratification according to 
each institute. Because this study was open label, we did 
not apply any masking procedures to study investigators 
or patients. The protocol was approved by the local 
institutional review board and scientific review boards 
prior to patient enrollment. This trial was also approved by 
the Ministry of Food and Drug Safety (MFDS, formerly 
known as the Korea Food and Drug Administration). 
Real-time monitoring of safety events was overseen by an 
independent data and safety monitoring board. The study 
was done, in accordance with the Declaration of Helsinki, 
the International Conference on Harmonisation note for 
good clinical practice (Topic E6, 1996), and applicable 
regulatory requirements. The data were collected by the 
sponsor, who vouched for data accuracy (clinicaltrials.gov 
NCT 00807027). 
Standard TMZ chemoradiotherapy protocol
 Standard TMZ treatment included concurrent 
radiotherapy (60 Gy administered as 2-Gy fractions 5 days 
per week) and chemotherapy with TMZ (75 mg per square 
meter of body-surface area per day for a maximum of 49 
days). Maintenance treatment with TMZ began 4 weeks 
after the completion of radiotherapy at a starting dose of 
150 mg per square meter for 5 consecutive days of a 28-
day cycle, with an increase to 200 mg per square meter for 
subsequent cycles if treatment-related adverse events of 
grade 2 or higher were not noted. Maintenance TMZ was 
administered for up to 6 cycles.
Generation of CIK cells and schedule of adoptive 
immunotherapy
For the autologous CIK immunotherapy group, 
peripheral blood ( > 120 ml) was collected from each 
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patient at least 2 weeks before administration. This study 
used commercialized CIK cell agents manufactured in a 
GMP-certified central facility (Green Cross Cell Cop., 
Korea) following surgical procedure under strict control 
of quality and assurance, whereas the CIK cell preparation 
was performed by their own cultivating methods in the 
previous studies [15-17]. In brief, mononuclear cells 
were separated and cultured for 12-21 days with IL-2 
and immobilized monoclonal antibody to CD3 at 37℃. 
The CIK cell agent contained a total of 109~2 x1010 cells 
in 200 mL of fluid consisting of 1% human albumin in 
normal saline. Immunotherapy group received CIK cell 
agent intravenously over 60 min, and were then observed 
for at least 30 min. They were scheduled to receive 
CIK cell agent 14 times (4 times at a frequency of once 
a week, followed by 4 times every 2 weeks, and finally 
6 times every 4 weeks). CIK cells were administered 
at an outpatient clinic. Treatment could be delayed for 
maximum of 2 weeks under the following condition; 1, 
delay of patient’s visit from his own schedule; 2, delay 
of treatment because of severe adverse effects; 3, in 
cases of contamination of CIK cells. Cytokines such as 
IFN, chemotherapeutic agents, other immunotherapeutic 
agents, hormonal therapy, and stem cell therapy were 
contraindicated during the study. The final cell products 
were assessed for viability by the dye-exclusion test, and 
checked twice for possible contamination by mycoplasma, 
sterility and endotoxin test. 
Eligibility
Patients enrolled in the study were aged 18 to 
70 years; had a Karnofsky performance status (KPS) 
of at least 60; newly diagnosed GBM (World Health 
Organization [WHO] grade IV astrocytoma; with adequate 
hematologic, renal and hepatic function; and acceptable 
blood coagulation levels) as confirmed on central review. 
Patients were excluded if they received any prior therapy 
or had evidence of HIV-positive, immune-deficiency 
disease or auto-immune diseases such as rheumatoid 
arthritis, systemic lupus erythematosus, multiple sclerosis, 
or juvenile-type insulin-dependent diabetes mellitus, 
history of severe allergy, serious cardiac disease or a prior 
malignancy (except melanoma, cervical cancer in situ., 
and localized prostate cancer). Pregnant or breast feeding 
women were also excluded. 
Assessment of clinical responses
At baseline, all patients underwent a physical 
examination that included a neurologic assessment, 
complete blood counts, blood chemical analyses 
(including tests of renal and hepatic function), and tumor 
imaging with magnetic resonance imaging (MRI). Patients 
were invited to participate in a longitudinal evaluation 
of the net clinical benefits of the treatment with the 
use of a validated test for quality of life (the European 
Organization for Research and Treatment of Cancer 
(EORTC) quality of life questionnaire with a brain-cancer 
module (QLQ-C30). During radiotherapy, patients were 
assessed for adverse events weekly, and underwent weekly 
complete blood counts and blood chemical analyses. 
During the maintenance phase of treatment, patients 
underwent complete blood counts and blood chemical 
analyses on days 21 and 35 of each cycle.
Progression-free survival was assessed locally by 
investigators on the basis of enhanced MRI was performed 
approximately 4 weeks after chemoradiotherapy, then at 
10, 22, 34 and 46 weeks after randomization, and every 
3~12 months thereafter during the follow-up phase. 
In addition to investigator-assessed progression, two 
radiologists at an independent review facility analyzed 
all MRI scans. The independent reviewers were unaware 
of the study-group assignments, with read-only access 
to previous reviews until the final imaging data set was 
reviewed. Response was assessed with the use of serial 
measures of the product of the two largest cross-sectional 
diameters, and progression was defined as an increase in 
tumor size by at least 25% or the development of a new 
lesion based upon Macdonald criteria, integrating patient’s 
general condition, infiltrative patterns on the T2/ FLAIR 
image, measurement of cerebral blood volume [18, 19]. 
Toxic effects were recorded and graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE), version 3.0. 
Data analysis and statistical considerations
 The primary endpoint was progression-free 
survival (PFS), and the goal of this study is to show that 
the addition of autologous CIK cells immunotherapy 
to a standard TMZ chemoradiotherapy would improve 
the PFS, as compared with the standard TMZ treatment 
alone. Secondary end points include overall survival 
(OS), objective responsive rate (ORR), disease control 
rate (DCR), Quality of life (QoL), KPS and assessment 
of adverse effects. PFS was calculated from the date 
of randomization either until disease progression was 
confirmed on the MR imaging or death from any causes. 
OS was calculated from the date of randomization until 
death from any cause. Objective response rate (OCR) was 
defined as either a partial or complete response and disease 
control rate (DCR) as partial, complete response or stable 
disease. 
 Sample size for the study was determined on 
the basis of PFS. Assuming a one-sided type I error of 
0.05, a power of 80%, and a randomization ratio for 1:1 
between two groups, 86 recurrence or death events were 
needed to detect a 20% difference (50% vs. 30%) in 
12-month PFS. [16] When the potential “loss to follow-
up” rate was set at 20%, 180 patients were required to 
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record 86 recurrence or death events. The intention-to-
treat (ITT) set was used to evaluate efficacy and included 
all randomized patients. The patients who completed 
treatment as planned were included in the per protocol 
set (PP set). Therapeutic outcomes were assessed based 
on the ITT set. Kaplan-Meier curves were generated for 
PFS and OS, and the log-rank test was used for group 
comparisons. A Cox’s proportional hazard analysis was 
done to assess the treatment effect after adjustment for 
baseline characteristics.
Adverse events were compared between two groups 
by chi-square or Fisher’s exact test. The log-rank test 
for the primary endpoint was one-sided, and all other 
statistical tests were two-sided. Statistical significance 
was set at P < .05. Statistical analysis was performed 
by statistician in the Department of Statistics at Korea 
university (Seoul, Korea) using SAS software version 9.2 
(SAS Institute Inc., Cary, NC, USA).
Study oversight
This trial was sponsored by Green Cross Cell 
company. We conducted the study at 7 sites. The 
steering committee provided oversight of the overall 
scientific integrity of the study. The protocol (available 
in supplementary file) was approved by the applicable 
independent ethics committees and institutional review 
boards. The study adhered to the principles of the 
Declaration of Helsinki and the Guidelines for Good 
Clinical Practice. The first draft of the manuscript was 
written by the first author with support from all coauthors; 
all authors reviewed and approved the manuscript. The 
data were collected by the sponsor and were analyzed by 
the statistician, 4th author (JW Lee). All the authors vouch 
for the completeness and accuracy of the data and confirm 
that the study was conducted according to the protocol.
RESULTS
Study patients
From December 2008 to October 2012, a total of 
188 patients were screened from 7 institutes in Korea, 8 
patients failed in the screening process, and 180 patients 
were randomized. 91 patients were randomized to the CIK 
immunotherapy group and 89 patients were randomized to 
the control group (Figure 2). 140 subjects were included 
in the per protocol set. The median age at the time of 
randomization was 55.0 and 54.0 years, with a range 19 
to 69 and 23 to 68 years in each group. Males comprised 
56.0% and 57.3% in each group, and all patients had KPS 
> 60 at the start of the study treatment (Table 1). Baseline 
characteristics except for the size of tumor were well 
balanced between the two treatment groups. Patients in 
the CIK immunotherapy group received the CIK cell agent 
containing 6.55 x 109 cells per a treatment (Table 2). 
Efficacy outcomes
In ITT set, median PFS was 8.1 months (95% 
confidence interval (CI), 5.8 to 8.5 months) in the CIK 
immunotherapy group, as compared to 5.4 months (95% 
Figure 1: Treatment scheme.
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CI, 3.3 to 7.9 months) in the control group (one-sided 
log-rank, p = 0.0401, hazard ratio 0.745 (90% CI, 0.564 
to 0.985) (Table 3). Cox proportional hazard model 
with the baseline characteristics that might be clinically 
related with the efficacy endpoint was fitted with stepwise 
procedure. Treatment group was selected in ITT and 
PP set. The results showed the consistency in statistical 
significance (one-sided test for the treatment effect: ITT 
set: p = 0.0413, PP set: p = 0.0229, data not shown). 
The PFS rates with CIK immunotherapy group and 
control group were 28.3% and 22.6% at 1 year, and 18.4% 
and 13.4% at 2 years, respectively (Table 3). Considering 
the effect of accompanying steroid medication when 
interpreting tumor change on MRI, we identified that there 
was no significant difference in the steroid medication 
between both groups (Chi-square test, p = 0.60). In PP set, 
median PFS was 8.1 months (95% CI, 7.1 to 8.9 months) 
in the CIK immunotherapy group and 5.4 months (95% 
CI, 4.0 to 7.9 months) in the control group (one-sided 
log-rank, p = 0.0218, hazard ratio 0.693 (90% CI, 0.512 
to 0.937)) (Supplementary Table 1). The median OS was 
22.5 months (95% CI, 17.2 to 23.9 months) in the CIK 
immunotherapy group, as compared with 16.9 months 
(95% CI, 13.9 to 21.9 months) in the control group, 
However, our results did not show a statistically significant 
difference in OS between the two groups (two-sided log-
rank test, p = 0.5237) (Table 4). Cox’s proportional hazard 
model was fitted in the same way as PFS, and treatment 
group and tumor size were selected in both ITT set and 
PP set and the results showed the consistency in statistical 
significance (two-sided test for the treatment effect: ITT 
set: p = 0.5069, PP set: p = 0.4145, data not shown).
There was no significant difference in the ORR 
including complete or partial response between groups 
(27.1% vs. 15.9%, P = 0.0783). However, a significant 
difference was found between groups in the DCR 
including complete response, partial response, and no 
change (82.4% vs. 63.4%, P = 0.0058) (Supplementary 
Table 3). 
Quality of life
All patients were required to complete the quality 
of life questionnaire. Global health status scores of the 
Table 1: Patient baseline characteristics and demographics (intention-to-treat set)
Patient Characteristics
CIK immunotherapy group Control group
N = 91 N = 89
n (%) n (%)
Age (years)
Mean ± SD 53.3 ± 10.8 52.8 ± 10.5
Median 55.0 54.0
Min, Max 19.0-69.0 23.0-68.0
Sex
Male 51 (56.0) 51(57.3)
Female 40 (44.0) 38(42.7)
Extent
of resection
Gross total resection 44 (48.4) 48(53.9)
Subtotal resection 27 (29.7) 25(28.1)
Partial resection 8 (8.8) 6(6.7)
Biopsy only 12 (13.2) 10(11.2)
Karnofsky 
performance scale
Mean ± SD 84.4 ± 12.8 85.7 ± 13.1
Median 90.0 90.0
Min, Max 60.0-100.0 60.0-100.0
Global health status/ 
quality of life
n 86 85
Mean ± SD 55.620 ± 22.340 54.314 ± 22.442
Median 58 50
Min, Max 8.0-100 0.0-100
Days from diagnosis to 
Baseline (Week 0)∆
Mean ± SD 21.6 ± 8.2 23.0 ± 9.5
Median 21.0 22.0
Min, Max 7.0-51.0 7.0-67.0
Days from surgery to 
Baseline (Week 0)⌂
Mean ± SD 27.4 ± 8.1 28.7 ± 9.0
Median 27.0 28.0
Min, Max 10.0-55.0 9.0-69.0
Tumor size (cm) 
Mean ± SD 5.7 ± 6.3 5.1 ± 10.4
Median 4.2 1.4
Min, Max 0.0-28.2 0.0-67.1
∆: The date of first diagnosis – Baseline + 1
⌂: Surgery date – Baseline
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EORTC QLQ-C30 significantly worsened after both 
treatments, but there was no significant difference of 
change between the groups (P = 0.6409). In the detailed 
functional scales, there were no significant group-wise 
differences in physical, role, emotional, cognitive, and 
social functioning. In addition, symptom scales such as 
fatigue, nausea and vomiting, pain, dyspnea, insomnia, 
appetite loss, constipation, diarrhea, and financial 
difficulties did not show any significant difference between 
two groups. (Supplementary Table 4). On the KPS scale, 
there was no significant difference between two groups 
(Supplementary Table 5). 
Safety
Treatment-emergent adverse events (TEAEs) of 
any grade were reported in 84 (98.8%) of patients who 
received CIK immunotherapy group, and 83 (97.6%) of 
the control group (Table 5). The incidences of total and 
≥ grade 3 were higher in the CIK immunotherapy group 
than the control group. However, there was no significant 
difference between groups (Supplementary Table 7). We 
did not find a significant difference in the rate of serious 
adverse events (41.2% vs. 36.5%, P = 0.5290), and in the 
rate of ≥ grade 3 adverse events (47.1% vs. 36.5%, P = 
0.1616) (Supplementary Table 6). The incidences of total 
and ≥ grade 3 adverse drug reactions (ADRs) associated 
with CIK immunotherapy group was 16 patients (18.8%) 
and 3 patients (3.5%), respectively (7 events). Each 
case involved neutropenia in 5 events from 1 patient, 
pneumonia in 1 case, and acute renal failure in 1 case 
(Supplementary Table 8). No therapy was discontinued 
due to treatment-related complications. Cytokine storm 
or anaphylactic reactions were not observed during this 
clinical trial.
Table 2: Summary of injected CIK cell agents (Safety set).
Immunotherapy
( n = 85)
Total cell count (x109)
Mean ± SD 6.55 ± 2.37
Range 1.20-19.60
Cell viability (%)
Mean ± SD 97.81 ± 2.11
Range 90.00-100.00
CD3+ cell (%)
Mean ± SD 98.63 ± 2.13
Range 80.50-100.00
CD8+ cell (%)
Mean ± SD 83.67 ± 7.83
Range 60.00-98.70
CD56+ cell (%)
Mean ± SD 28.23 ± 12.46
Range 10.00-90.40
CD14+ cell (%)
Mean ± SD 0.04 ± 0.07
Range 0.00-0.60
CD20+ cell (%)
Mean ± SD 0.15 ± 0.15
Range 0.00-0.90
n (%)
Injection times
0 6 (6.59)*
1 1 (1.10)
3-4 2 (2.20)
6-10 25 (27.47)
12-13 17 (18.68)
14 40 (43.96)
Total injection no. 997
* 2 withdrew consent, 1 progression, 1 death, 1 deterioration, 1 miscellaneous
Note. There is no one who has been injected 2, 5, 11 times.
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DISCUSSION
Recently, immunotherapy is an emerging candidate 
for alternative treatment options for a variety of cancers. 
[3, 14, 15, 17] Immunotherapy has recently evolved in the 
oncology field with therapeutic benefits and combinatorial 
regimen with cytotoxic agents is known to potentiate anti-
tumor immune function. 
CIK cells have anti-tumor activity via secretion 
of cytotoxic molecules and the production of multiple 
cytokines that regulate immune responses. [17] Adoptive 
cell therapy is a highly personalized cancer therapy that 
involves administration to the cancer-bearing host of 
immune cells with direct anticancer activity. Adoptive 
cell therapy provides a favorable microenvironment 
that better supports antitumor immunity. Such an 
immunotherapy would be more beneficial when residual 
tumors are minimal, such as in cases of postoperative 
adjuvant treatment. [16] This study was designed 
to determine whether adding autologous CIK cells 
immunotherapy to the first-line treatment for GBM would 
improve patient outcomes. We found that autologous 
CIK cells immunotherapy combined with standard 
chemoradiotherapy with TMZ was associated with a 2.7 
months increase in median PFS in the newly diagnosed 
GBM. These results were comparable to the recently 
published clinical trials with Bevacizumab. [20, 21] 
In particular, autologous CIK immunotherapy group 
showed a higher DCR than the control group (82.4% vs. 
63.4%, P = 0.0058). Furthermore, CIK immunotherapy 
adding to conventional temozolomide treatment did not 
induce additional deterioration of QoL, compared with 
the control group. It can be interpreted that maintenance 
of QoL could be a relevant treatment goal of CIK 
immunotherapy. Several studies have demonstrated the 
critical role of immunotherapy as an adjuvant treatment 
for residual or remnant caner. [6, 13] However, this was 
the first prospective randomized controlled study of 
CIK immunotherapy for newly diagnosed GBM. Our 
results raised the question of why anti-tumor activity 
of autologous CIK immunotherapy did not prolong the 
Table 3: Progression-free survival (PFS) in the intention-to-treat set
CIK immunotherapy group (N = 91) Control group (N = 89)
  No. of events (Death or PD), n (%) 70 (76.9%) 71 (79.8%)
  Median PFS [95% CI] 8.1 [5.8, 8.5] 5.4 [3.3, 7.9]
PFS rate (%)
  12 months (%) [95% CI] 28.3 [19.0, 38.3] 22.6 [14.3, 32.1]
  18 months (%) [95% CI] 25.6 [16.7, 35.5] 21.2 [13.1, 30.6]
  24 months (%) [95% CI] 18.4 [10.7, 27.9] 13.4 [6.8, 22.3]
p-value1) 0.0401#
Hazard ratio [90% CI]2) 0.745 [0.564, 0.985]
PD, progressive disease
* Progression-free survival=Diagnosis date of disease progression by MRI, date of death or date of off-study - Randomization 
date
1) Results by one-sided Log-rank test 
2) Presented as the result of one-sided test
# p-value < 0.05
Table 4: Overall survival (OS) in the intention-to-treat set
CIK immunotherapy group (N = 91) Control group (N = 89)
Incidence rate (Death), n (%) 51 (56.04) 52 (58.43)
Median OS [95% CI] 22.47 [17.20, 23.85] 16.88 [13.91, 21.94]
OS rate (%)
12 months (%) [95% CI] 78.22 [67.64, 85.69] 75.24 [64.26, 83.27]
18 months (%) [95% CI] 57.24 [45.27, 67.51] 45.08 [33.55, 55.93]
24 months (%) [95% CI] 38.21 [26.77, 49.54] 38.49 [27.22, 49.63]
p-value1) 0.5237
Hazard ratio [90% CI]2) 0.693 [0.512, 0.937]
* Overall Survival=Date of death or date of off-study - Randomization date
1) Results by Log-rank test
2) Presented as the result of one-sided test
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Figure 3: Kaplan-Meier plot of progression-free survival as assessed by investigator A. and overall survival B.
Figure 2: Paradigm of clinical trial for management of the newly diagnosed patients with glioblastoma. 
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survival in this study, unlike previous phase II studies. 
BBB serves as a boundary that separates the peripheral 
circulation and the central nervous system, which 
inherently may prevent immune reaction in the brain. The 
efficacy of immunotherapy may depend upon the integrity 
of the BBB. As a result, immunotherapy may be more 
effective in advanced or recurrent cancer settings. Similar 
to CIK immunotherapy, randomized trials of bevacizumab 
or cilengitide added to standard chemoradiotherapy with 
TMZ in newly diagnosed GBM did not extend OS. [20-22] 
These results demonstrated that additional confirmative 
evidences are required before moving into definitive large-
scale phase III study for newly diagnosed GBM. [22]
The limitation of this study is the lack of information 
about the molecular biomarkers in the GBM. Pre-informed 
stratification based upon the methylation status of O6-
Methylguanine-DNA Methyltransferase (MGMT) gene 
promoter or isocitrate dehydrogenase 1 gene (IDH1) 
mutation must have enforced the power of the result in 
this study. In addition, the identification of surrogate 
immunologic biomarkers will accelerate the establishment 
of more successful immunotherapeutic strategies. 
In summary, CIK immunotherapy for newly 
diagnosed GBM did not show statistically significant 
difference in OS but resulted in a significantly prolonged 
PFS, with relative maintenance of QoL and functional 
status. Significant adverse events related to treatment 
were not observed, and no adverse events appeared to 
be related to cytotoxicity. We did not identify a subgroup 
of patients who had a selected survival benefit from the 
CIK immunotherapy group. Further investigations of 
molecularly defined subgroups may uncover a predictive 
marker panel for autologous CIK immunotherapy, which 
would require additional prospective testing.
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